Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
There is increasing evidence for an alternative pathway of sporadic colorectal tumourigenesis that is associated with DNA microsatellite instability (MSI), due to methylation and loss of expression of the mismatch repair gene MLH1 . Recent studies have highlighted a serrated pathway of colorectal cancer (CRC) in which serrated polyps with activating mutations in BRAF progress to CRCs with MSI following methylation and silencing of MLH1 . The present study provides a novel mechanistic experimental model for these clinical observations. We investigated the role of BRAF activating mutation (BRAF‐V600E) in colorectal tumourigenesis by studying the effects of forced expression of BRAF‐V600E in the ‘normal’ colon epithelial NCM460 cell line and by targeting endogenous BRAF‐V600E in MSI‐High (MSI‐H) colon cancer cell lines. The findings indicate that BRAF mutation in colon epithelial cells contributes to a gain in resistance towards apoptotic stimuli, which is likely to be an important characteristic of pre‐malignant serrated lesions. BRAF‐V600E also plays a role in the development and maintenance of transformed and invasive phenotypes in colon epithelial cells. Our findings also suggest that BRAF mutation potentiates promoter hypermethylation of the MLH1 gene promoter. Together, these results highlight BRAF as a potential target for therapeutic intervention in sporadic MSI‐H colorectal cancers. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“It has been shown that forced BRAF-V600E expression in human melanocytes induces cell cycle arrest and induction of, and progression to, senescence [48], while inactivation of p16 expression is required for melanomagenesis [53–55].”
BackgroundHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“Oncogenic mutations of BRAF, most frequently BRAF-V600E, have been reported in colon cancer, melanoma, papillary thyroid carcinoma and other cancers [41,42].”
BackgroundLin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
The power and the promise of oncogene-induced senescence markers
Collado, M., & Serrano, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1884 · Cited by 404
Cited by
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors
Agaram, N. P., Wong, G. C., Guo, T., Maki, R. G., Singer, S., DeMatteo, R. P., Besmer, P., & Antonescu, C. R. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20589 · Cited by 388
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“Also, a portion of cancers negative for MLH1/PSM2 by immunohistochemistry belong to this group of CIMPþ tumours.(61,62) Colorectal carcinomas can further be classified into four molecular subtypes according to their CIMP and MSI statuses: CIMPþ/MSIþ, CIMPþ/MSI , CIMP /MSIþ and CIMP /MSI .”
BackgroundCarragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
“This result is consistent with the observation that high DNMT3b expression is detected in CRCs with the methylator phenotype (Nosho et al, 2009) and with the fact that ectopic expression of V600EBRAF in normal human colon epithelial cells induces methylation of the MLH1 promoter (Minoo et al, 2007).”
Seth, R., Crook, S., Ibrahem, S., Fadhil, W., Jackson, D., & Ilyas, M. (2009) · Gut · doi:10.1136/gut.2008.159137 · Cited by 66
“promoter. Thus selection for highly active mutations may explain the bias towards the V600E”
Background
Metadata
- Authors
- Minoo, P., Moyer, M., & Jass, Jr.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2007-05-11
- Volume
- 212
- Issue
- 2
- Pages
- 124-133
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2071070516
- Cited by
- 92
- References
- 5
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.